# Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis

> **NCT04871945** · — · COMPLETED · sponsor: **Hanyang University Seoul Hospital** · enrollment: 31 (actual)

## Conditions studied

- Covid19
- Vaccine Reaction
- Hemolysis
- End-stage Renal Disease

## Interventions

- **DIAGNOSTIC_TEST:** Elecsys Anti-SARS-CoV-2 S (Roche Diagnostics GmbH, Mannheim, Germany), 2) ACCESS SARS-CoV-2 IgG II (Beckman Coulter, Inc. USA)

## Key facts

- **NCT ID:** NCT04871945
- **Lead sponsor:** Hanyang University Seoul Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-20
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-10-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04871945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04871945, "Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04871945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*